Adcetris® (brentuximab vedotin) – New indication
November 10, 2022 - Seagen announced the FDA approval of Adcetris (brentuximab vedotin), for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
Top